Efficacy and Safety of Precision Therapy in Refractory Tumor

Summary

This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.

Conditions

• Rare Tumor
• Refractory Tumor

Interventions

DRUG

Gefitinib

Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.

DRUG

Erlotinib

Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.

DRUG

Afatinib

Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.

DRUG

Trastuzumab

Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.

DRUG

Oxazolidine

Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.

DRUG

Olaparib

Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.

DRUG

Everolimus

Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.

DRUG

Cabozantinib

Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.

DRUG

Vemurafenib

Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.

DRUG

Dabrafenib

Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.

DRUG

Palbociclib

Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.

DRUG

PD-1/L1 inhibitor plus anti-angiogenic agent

PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target

Sponsors & Collaborators

• Baodong Qin

  lead OTHER

Principal Investigators

• Yuan-Sheng Zang, MD.PHD · Shanghai Changzheng Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-01-01

Primary Completion

2023-06-30

Completion

2023-12-31

Countries

• China

Study Locations